Physician profile
Eric R Gejer
NPI 1104863067
$2,989.61
in general payments reported to CMS, 2019-2025
22 companies · $102 in 2025
The $102 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $539 · 2020: $378 · 2021: $476 · 2022: $397 · 2023: $643 · 2024: $454 · 2025: $102.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,199.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $576.36 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $525.53 | 2019-2024 | Xarelto |
| Amgen INC. | $329.67 | 2020-2025 | Repatha |
| E.R. Squibb & Sons, L.L.C. | $287.92 | 2019-2025 | Eliquis, Camzyos |
| Merck Sharp & Dohme LLC | $170.17 | 2021-2025 | Verquvo |
| Medtronic, INC. | $157.78 | 2022-2025 | Interstim |
| Pfizer INC. | $146.91 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $134.44 | 2019-2023 | Farxiga |
| Amarin Pharma, INC. | $125.76 | 2019-2022 | |
| Kiniksa Pharmaceuticals International, Plc | $103.86 | 2024 | Arcalyst |
| Boehringer Ingelheim Pharmaceuticals, INC. | $97.55 | 2019-2024 | Jardiance |
| Boston Scientific Corporation | $85.11 | 2023 | Watchman Access System |
| Actelion Pharmaceuticals US, INC. | $51.10 | 2022-2023 | Uptravi, Opsumit |
| Sanofi-Aventis U.S. LLC | $47.91 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $25.73 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $24.53 | 2023-2024 | Lifevest |
| Esperion Therapeutics, INC. | $20.34 | 2024 | Nexletol |
| Edwards Lifesciences Corporation | $18.35 | 2019 | |
| Kiniksa Pharmaceuticals, LTD. | $17.48 | 2023 | Arcalyst |
| Novo Nordisk INC | $16.96 | 2023 | Rybelsus, Ozempic |
| Daiichi Sankyo INC. | $15.21 | 2023 | Injectafer |
| Lantheus Medical Imaging, INC. | $10.94 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Gejer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.